secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-126731
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q3 2024: cash $183M, 40 U.S. sites recruiting; EMA greenlights lupus trial
--------------------------------------------------------------------------------

- R&D expenses $26.3M (up 91% YoY); G&A $6.8M (up 39%); cash $183.0M expected to fund ops into H1 2026.
- 16 patients enrolled, 10 dosed across RESET program as of Nov 12; 40 U.S. clinical sites actively recruiting.
- EMA allowed CTA for RESET-SLE trial in Europe; myositis, lupus, scleroderma data presented at ACR weekend.
- Gerwin Winter appointed SVP Head of International; Nicolette Sherman named CHRO replacing retiring Martha O'Connor.
- Investor call Nov 18 to review ACR data; Jefferies London conference Nov 20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000095017024126731/0000950170-24-126731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000095017024126731/caba-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer